Biolexis Therapeutics, a preclinical-stage biopharmaceutical company, is leveraging AI and machine learning to develop small-molecule therapeutics targeting various diseases for precision medicine. The company's FIELDS platform uses advanced AI/ML techniques to generate accurate protein structure models, providing a deeper understanding of proteins' functions and their effects on cellular structures. By utilizing the Anyscale Platform and Ray, Biolexis can scale its workload and accelerate scientific outcomes, reducing costs and increasing the probability of success in clinical trials. The platform enables seamless scaling of workloads, parallelization of processes, and simplified deployment to production without requiring a dedicated infrastructure team.